By Conor Grant
This is an edition of the WSJ Health newsletter, a weekly briefing on what's new in health, medicine, personal well-being and the business of healthcare. If you're not subscribed, sign up here.
The newsletter won't publish the Friday after Thanksgiving. Your next edition will arrive the following week. Enjoy the break!
In the News
For many kids, ADHD pills are the start of a drug cascade. The next steps are often powerful psychotropic drugs -- including antipsychotics, antidepressants and sleep aids -- even though their combined effects in young children haven't been studied closely.
Separately, the founder of an ADHD startup was found guilty of conspiracy. Ruthia He, whose company Done Global was the subject of a WSJ investigation, was accused of orchestrating a scheme to profit from Adderall prescriptions.
Trump administration officials discussed curbing the role of the FDA commissioner, Marty Makary, after complaints about his management style, though the idea was dropped.
Your Well-Being
The FDA called for the removal of its strongest warning on hormone treatments, which were once commonly prescribed to combat declining estrogen levels in middle-aged women. Here's how to understand the new guidance.
Medicaid insurers promise many doctors, but actually seeing one can be difficult. Many medical professionals listed in insurer networks treat few or no Medicaid recipients, leaving patients with long waits.
The Business of Health
The weight-loss craze could soon mint a trillion-dollar company. Shares of Eli Lilly have room to keep rising as the market for GLP-1 drugs continues to expand, writes David Wainer.
Roche shares rose after its breast-cancer pill showed positive results in a recent late-stage clinical trial. Analysts have estimated that the experimental drug, giredestrant, could generate around $5 billion in sales for the drugmaker.
About Us
The Health newsletter gives you a weekly briefing on what's new in health, medicine, personal well-being and the business of healthcare.
(END) Dow Jones Newswires
November 21, 2025 09:55 ET (14:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.